Cargando…

Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report

Symptomatic colon metastasis from primary lung cancer is rare in clinical practice. We report the case of a 58-year-old patient with advanced lung adenocarcinoma who developed abdominal symptoms, including abdominal distention and difficulty defecating, after immunotherapy and chemotherapy. The pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Luo, Yuhao, Mou, Kelin, Wang, Jianmei, Luo, Jing, Peng, Lin, Ye, Hua, Lin, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393296/
https://www.ncbi.nlm.nih.gov/pubmed/36003386
http://dx.doi.org/10.3389/fimmu.2022.970879
_version_ 1784771241172795392
author Luo, Yuhao
Mou, Kelin
Wang, Jianmei
Luo, Jing
Peng, Lin
Ye, Hua
Lin, Sheng
author_facet Luo, Yuhao
Mou, Kelin
Wang, Jianmei
Luo, Jing
Peng, Lin
Ye, Hua
Lin, Sheng
author_sort Luo, Yuhao
collection PubMed
description Symptomatic colon metastasis from primary lung cancer is rare in clinical practice. We report the case of a 58-year-old patient with advanced lung adenocarcinoma who developed abdominal symptoms, including abdominal distention and difficulty defecating, after immunotherapy and chemotherapy. The patient was diagnosed with lung adenocarcinoma, and systemic positron emission tomography-computed tomography confirmed multiple lymph node, pleural, and adrenal metastases. Molecular detection indicated BRAF V600E mutation and high programmed death-ligand 1 (PD-L1) expression. After first-line anti-programmed cell death protein 1 immunotherapy combined with chemotherapy, the nodes in the chest remarkably diminished. However, it was followed by colon obstruction, incomplete ileus, and bone metastasis. Endoscopic histological examination confirmed adenocarcinoma but could not identify primary or secondary tumors due to insufficient tissue. We performed colon resection to remove the obstruction, and postoperative tissue pathological microscopy confirmed metastasis from the lung adenocarcinoma. We corroborated the BRAF V600E mutation and high PD-L1 expression and supported the molecular features of lung adenocarcinoma. During hospitalization, the patient presented with unbearable pain in the bone metastases, and palliative radiotherapy was administered. Then, the patient received dabrafenib plus trametinib as the second-line therapy. This report discusses the clinical characteristics, pathology, imaging, molecular profile assessments, and treatment of primary lung adenocarcinoma with colon metastasis.
format Online
Article
Text
id pubmed-9393296
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93932962022-08-23 Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report Luo, Yuhao Mou, Kelin Wang, Jianmei Luo, Jing Peng, Lin Ye, Hua Lin, Sheng Front Immunol Immunology Symptomatic colon metastasis from primary lung cancer is rare in clinical practice. We report the case of a 58-year-old patient with advanced lung adenocarcinoma who developed abdominal symptoms, including abdominal distention and difficulty defecating, after immunotherapy and chemotherapy. The patient was diagnosed with lung adenocarcinoma, and systemic positron emission tomography-computed tomography confirmed multiple lymph node, pleural, and adrenal metastases. Molecular detection indicated BRAF V600E mutation and high programmed death-ligand 1 (PD-L1) expression. After first-line anti-programmed cell death protein 1 immunotherapy combined with chemotherapy, the nodes in the chest remarkably diminished. However, it was followed by colon obstruction, incomplete ileus, and bone metastasis. Endoscopic histological examination confirmed adenocarcinoma but could not identify primary or secondary tumors due to insufficient tissue. We performed colon resection to remove the obstruction, and postoperative tissue pathological microscopy confirmed metastasis from the lung adenocarcinoma. We corroborated the BRAF V600E mutation and high PD-L1 expression and supported the molecular features of lung adenocarcinoma. During hospitalization, the patient presented with unbearable pain in the bone metastases, and palliative radiotherapy was administered. Then, the patient received dabrafenib plus trametinib as the second-line therapy. This report discusses the clinical characteristics, pathology, imaging, molecular profile assessments, and treatment of primary lung adenocarcinoma with colon metastasis. Frontiers Media S.A. 2022-08-08 /pmc/articles/PMC9393296/ /pubmed/36003386 http://dx.doi.org/10.3389/fimmu.2022.970879 Text en Copyright © 2022 Luo, Mou, Wang, Luo, Peng, Ye and Lin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Luo, Yuhao
Mou, Kelin
Wang, Jianmei
Luo, Jing
Peng, Lin
Ye, Hua
Lin, Sheng
Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title_full Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title_fullStr Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title_full_unstemmed Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title_short Colon metastasis from lung adenocarcinoma with BRAF V600E mutation: A case report
title_sort colon metastasis from lung adenocarcinoma with braf v600e mutation: a case report
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9393296/
https://www.ncbi.nlm.nih.gov/pubmed/36003386
http://dx.doi.org/10.3389/fimmu.2022.970879
work_keys_str_mv AT luoyuhao colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT moukelin colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT wangjianmei colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT luojing colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT penglin colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT yehua colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport
AT linsheng colonmetastasisfromlungadenocarcinomawithbrafv600emutationacasereport